Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.61 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363476 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL2076614 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL7863455 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL29040497 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL29040501 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL19240717 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL3049211 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| Hydrochloric Acid SCHEMBL5279548 | 0.98 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| Hydrochloric Acid SCHEMBL6375520 | 0.98 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL335088 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4436610-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20230212110-A1 | CARBAMATE PRODUCTION METHOD, CARBAMATE ESTER PRODUCTION METHOD, AND UREA DERIVATIVE PRODUCTION METHOD | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2023-07-06 | — | — | US | disclosed |
| WO-2023091441-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3293175-B1 | METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3293175-A1 | METHODS FOR PURIFICATION OF SERINE PROTEASES | Portola Pharmaceuticals, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2938596-B1 | METHODS FOR PURIFICATION OF SERINE PROTEASES | PORTOLA PHARM INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-0517326-A2 | Labeled drug hapten analogues for immunoassays | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1992-12-09 | — | — | EP | disclosed |
| EP-0517325-A2 | Drug hapten analogues for immunoassays | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1992-12-09 | — | — | EP | disclosed |
| WO-1992009556-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GALARDY RICHARD E (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992009563-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GLYCOMED, INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992009282-A1 | TREATMENT FOR TISSUE ULCERATION | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| US-5114953-A | Peptides | UNIVERSITY OF FLORIDA (US) | 1992-05-19 | — | — | US | disclosed |
| EP-0240867-B1 | PROCESS FOR THE PREPARATION OF AMINOALKYL- OR -ARYLMELAMINES | BASF Aktiengesellschaft (DE) | 1992-02-19 | — | — | EP | disclosed |
| US-4670558-A | POLYURETHANE INTERMEDIATES | BASF AKTIENGESELLSCHAFT (DE) | 1987-06-02 | — | — | US | disclosed |
| EP-0179408-A2 | Amidoalkyl melamines and aminoalkyl melamines, and process for their preparation | BASF Aktiengesellschaft (DE) | 1986-04-30 | — | — | EP | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212110-A1 | CARBAMATE PRODUCTION METHOD, CARBAMATE ESTER PRODUCTION METHOD, AND UREA DERIVATIVE PRODUCTION METHOD | CPS1, ATM, OAT | HTT 1074/4885TGM2 169/4885LMNA 4448/4885 |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | HTT 603/4885TGM2 435/4885LMNA 3937/4885 |
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, INSR, IAPP | HTT 982/4885TGM2 659/4885LMNA 4837/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | HTT 603/4885TGM2 435/4885LMNA 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.